Lincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board approves Dividend
Lincoln Pharma board recommended a dividend of ₹1.80 per share (18%) for FY26. This is subject to approval at the upcoming Annual General Meeting.
May 28 2026 17:21:19
Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Quarter And Year Ended 31St March, 2026.
Lincoln Pharma's board approved audited consolidated financial results for FY26, reporting a net profit of ₹87.89 crore, up 6.74% YoY, and revenue of ₹704.48 crore, up 9.10% YoY. The company also recommended an 18% dividend of ₹1.80 per share for the fiscal year.
May 28 2026 17:09:01
Lincoln Pharmaceuticals Ltd - 531633 - Corporate Action-Board to consider Dividend
Lincoln board will meet on May 28, 2026, to consider a dividend recommendation for equity shares. The meeting also includes approval of audited financial results for the quarter and year ended March 31, 2026.
May 18 2026 14:42:19
Lincoln Pharmaceuticals Ltd - 531633 - Board Meeting Intimation for Consideration Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended On March 31, 2026.
Lincoln Pharma board meeting scheduled for May 28, 2026, to approve audited financial results for Q4 and year ended March 31, 2026, and to recommend a dividend for shareholders.
May 18 2026 14:35:59
Read More